The Alliance for Regenerative Medicine Released Agenda for Sixth Annual Advanced Therapies Summit

WASHINGTON, DC--(Marketwired - Mar 17, 2016) - The Alliance for Regenerative Medicine (ARM) today released the complete agenda for its sixth annual Advanced Therapies Summit, taking place April 6, 2016 in Stockholm, Sweden. This one-day meeting is a gathering of the sector's top executives, clinical researchers and policymakers across Europe and the United States to discuss how best to support the Advanced Therapies Medicinal Products (ATMP) sector.

This multi-stakeholder, interactive forum features five roundtable discussions led by sector experts representing international advanced therapies organizations in the gene therapy, cell therapy and regenerative medicine community. The event also offers attendees ample networking opportunities to engage with other sector stakeholders, including top company executives, clinical researchers, public policymakers and other members of the advanced therapies community.

"The Advanced Therapies Summit provides the perfect opportunity for discussion and the exchange of ideas within the ATMP community," said Alexander Vos, CEO of PharmaCell. "This forum will cover the most pressing issues our sector is facing today, the timing couldn't be better. PharmaCell is very pleased to be able to support this vital interaction."

2016 Roundtables and Discussion Leaders:
Roundtable I: Industrialization of Cell Therapy
Sylvain Arnould, Head of Manufacturing, Cellectis
Dieter Hauwaerts, Vice President of Operations, Celyad
Keith Thompson, CEO, Cell and Gene Therapy Catapult
Giuliana Vallanti, Ph.D., Head of Development and Quality Control, MolMed
Phil Vanek, Ph.D., General Manager, Cell Bioprocessing, GE Healthcare Life Sciences

Roundtable II: ATMP Development & Regulatory Challenges
Eduardo Bravo, CEO, TiGenix
Anne-Virginie Eggimann, Vice President, Regulatory Science, bluebird bio
Paula Salmikangas, Ph.D., Chair, Committee for Advanced Therapies (CAT), European Medicines Agency (EMA)
Carmen Vieira, Pharm.D., Associate Director of Regulatory Affairs -- EMEA, Janssen Research & Development

Roundtable III: Pharma's Strategic Investment in Gene & Cell Therapy
Sven Kili, Gene Therapy Development Head, GlaxoSmithKline
Edward Lanphier, CEO, Sangamo BioSciences
Mathieu Simon, M.D., Executive Vice President, Chief Operating Officer, Cellectis
Jeff Till, Ph.D., Director, External Innovation, EMD Serono

Roundtable IV: Adaptive Pathways & Early Market Access